Isomorphic Labs introduced the Isomorphic Labs Drug Design Engine (IsoDDE), positioning it as a next step beyond structure-only predictions from AlphaFold 3. The company says IsoDDE more than doubled AlphaFold 3 accuracy on a protein–ligand generalization benchmark and can predict binding affinities with accuracy reportedly exceeding physics-based methods at lower time and cost. The platform preview also claims it can identify novel binding pockets using only amino-acid sequence input, aiming to bridge the gap between in-silico structure modeling and actionable drug-discovery predictions across biochemical properties. For biotech R&D teams, the announcement signals continued investment in foundation-model-driven drug design systems that integrate structure, binding, and generalization—capabilities needed for faster lead identification and tighter iteration cycles.